By the end of this note you will be able to recognise, grade and initiate the immediate work‑up and management of hepatic encephalopathy in a Kenyan clinical setting. Always verify drug choices, doses and local protocols against the Kenya Ministry of Health guideline and your hospital formulary.
Definition
A reversible neuropsychiatric syndrome caused by accumulation of neurotoxic substances—principally ammonia—in patients with acute or chronic liver dysfunction or portosystemic shunting.
Anatomy and physiology you need
| Structure | Relevance to HE |
|---|---|
| Hepatocytes | Detoxify ammonia (urea cycle) and other gut‑derived toxins |
| Portal vein | Carries ammonia‑rich blood from gut to liver |
| Portosystemic collaterals | Bypass the liver, allowing toxins to reach systemic circulation |
| Blood‑brain barrier (BBB) | Normally limits toxin entry; becomes permeable in liver disease |
| Astrocytes | Convert ammonia to glutamine; excess glutamine causes cellular swelling (cerebral edema) |
| Basal ganglia & cerebral cortex | Sites of altered neurotransmission producing the clinical spectrum of HE |
Causes and risk factors
| Category | Common Kenyan triggers |
|---|---|
| Cirrhosis (any aetiology) | Alcoholic, viral hepatitis B/C, non‑alcoholic fatty liver disease |
| Acute liver failure | Viral hepatitis (A, E), drug‑induced (e.g., paracetamol), toxins |
| Portosystemic shunts | Spontaneous (cirrhosis) or iatrogenic (TIPS) |
| Precipitating factors | GI bleed, infection (spontaneous bacterial peritonitis, TB, malaria), electrolyte disturbance (hypokalemia, alkalosis), constipation, excess dietary protein, sedatives (benzodiazepines, opioids), renal dysfunction |
| HIV‑related | Advanced HIV with opportunistic infections, antiretroviral hepatotoxicity |
| Tuberculosis | Disseminated TB with hepatic involvement or anti‑TB drug hepatotoxicity |
| Malaria | Severe falciparum malaria causing hepatic congestion and hemolysis |
| Sickle cell disease | Chronic hemolysis and hepatic sequestration leading to cholestasis |
| Rheumatic fever / autoimmune hepatitis | Immune‑mediated liver injury |
| Pregnancy | Acute fatty liver of pregnancy, HELLP syndrome |
Pathophysiology
Gut bacteria produce ammonia → portal blood → ↓ hepatic clearance (cirrhosis, shunt) → ↑ systemic ammonia → crosses compromised BBB → astrocyte uptake → glutamine accumulation → astrocyte swelling → cerebral edema → altered neurotransmission (↑ GABAergic tone, ↓ excitatory pathways) → clinical encephalopathy.
Additional contributors:
- Inflammation → cytokine‑mediated BBB permeability.
- Oxidative stress → neuronal dysfunction.
- Altered manganese deposition → basal ganglia changes.
Causal chain (arrows):
Protein → gut bacteria → NH₃ → portal vein → impaired hepatic metabolism → ↑ systemic NH₃ → BBB dysfunction → astrocyte glutamine ↑ → cerebral edema → neuro‑inhibition → HE.
Clinical features
| Domain | Key questions to ask | Why it matters |
|---|---|---|
| Onset & course | When did the change start? Was it sudden or gradual? Any precipitating event (infection, GI bleed, medication change, surgery)? | Hepatic encephalopathy (HE) often follows a trigger that raises ammonia or other neurotoxins; rapid onset suggests an acute precipitant, while a slow decline may indicate chronic decompensation. |
| Mental status | Do you feel “foggy”, confused, sleepy, or have trouble concentrating? Any episodes of disorientation, agitation, or hallucinations? | The spectrum ranges from subtle neurocognitive impairment (minimal HE) to coma; mental status is the cornerstone of grading severity. |
| Asterixis | Do you notice a “flapping” when you hold your arms out? Has a caregiver observed tremor‑like movements? | Asterixis is a classic motor sign of cortical dysfunction caused by impaired astrocyte metabolism; its presence helps differentiate HE from other metabolic encephalopathies. |
| Sleep‑wake cycle | Do you nap excessively or have reversed sleep patterns? | Sleep disturbance is an early manifestation of cerebral ammonia toxicity. |
| Behavioral changes | Any irritability, aggression, or personality change? Any recent episodes of inappropriate laughter or crying? | Disinhibition and emotional lability reflect frontal lobe involvement. |
| Gastro‑intestinal symptoms | Nausea, vomiting, constipation, or recent GI bleed? Any recent use of laxatives or enemas? | GI bleeding and constipation increase ammonia production/absorption; they are common precipitants in our setting. |
| Medication & substance use | Current use of diuretics, lactulose, antibiotics, sedatives, or herbal remedies? Alcohol intake? | Diuretics and sedatives can precipitate HE; lactulose is both a treatment and a potential precipitant if stopped abruptly. |
| Infections | Fever, cough, dysuria, recent malaria, TB, or HIV‑related illness? | Infections are the leading precipitant in African hospitals; malaria, TB, and opportunistic infections raise systemic inflammation and ammonia. |
| Renal function | History of kidney disease, reduced urine output, or recent nephrotoxic drugs? | Renal impairment reduces ammonia clearance, worsening HE. |
| Past liver disease | Known cirrhosis, hepatitis B/C, alcoholic liver disease, schistosomiasis, sickle‑cell hepatopathy? | Underlying chronic liver disease sets the stage; tropical causes (schistosomiasis, sickle‑cell) are common in Kenya. |
| Nutritional status | Recent weight loss, poor protein intake, or high‑protein meals? | Both protein excess and severe malnutrition can affect ammonia generation and brain susceptibility. |
Examination findings and rationale
| Finding | What it indicates | Pathophysiologic basis |
|---|---|---|
| Asterixis (flapping tremor) | Cortical motor dysfunction | Interruption of thalamocortical pathways by astrocyte swelling due to ammonia. |
| West‑Haven grade (1‑4) | Severity of encephalopathy | Grading correlates with level of consciousness and risk of mortality. |
| Focal neurological deficits (absent) | Helps exclude stroke, space‑occupying lesion | HE is a diffuse metabolic process; focal signs suggest alternative diagnosis. |
| Miosis or mydriasis (absent) | Rules out opioid or anticholinergic toxicity | Pupillary changes are drug‑specific, not typical of HE. |
| Jaundice, spider angiomas, palmar erythema | Chronic liver disease | Visual clues to underlying hepatic insufficiency. |
| Ascites & peripheral edema | Portal hypertension & hypoalbuminemia | Fluid shifts reflect advanced cirrhosis, a common substrate for HE. |
| Auscultation: asterixis‑related tremor, hyperactive bowel sounds | Possible constipation or ileus | Reduced gut motility raises ammonia absorption. |
| Signs of infection (fever, tachycardia, lung crackles) | Infective precipitant | Systemic inflammation amplifies neurotoxic effects. |
| Scleral icterus, hepatomegaly | Acute liver injury (e.g., malaria‑related hepatitis) | Helps differentiate acute hepatic failure from chronic decompensation. |
| Neurological exam: normal reflexes, no neck rigidity | Excludes meningitis/encephalitis | Absence of meningeal signs supports metabolic encephalopathy. |
Differential diagnosis
| Condition | Points toward it | Distinguishing features |
|---|---|---|
| Hepatic encephalopathy | Known liver disease, asterixis, fluctuating mental status, precipitating infection or GI bleed | Improves with lactulose/antibiotics; ammonia often elevated; no focal neuro signs |
| Wernicke’s encephalopathy | Alcohol misuse, malnutrition, ophthalmoplegia, ataxia | Classic triad; MRI shows thalamic lesions; thiamine response |
| Uremic encephalopathy | Advanced renal failure, high BUN, no liver disease | Improves with dialysis; no asterixis |
| Septic encephalopathy | Fever, leukocytosis, source of infection, no liver disease | Rapid onset, diffuse slowing on EEG, resolves with infection control |
| Drug‑induced delirium (benzodiazepines, anticholinergics) | Recent medication change, anticholinergic signs, dry skin | Disappears after drug withdrawal; toxicology screen |
| Intracranial bleed / stroke | Sudden focal deficits, headache, papilledema | CT/MRI shows bleed or infarct; focal signs present |
| Meningitis/encephalitis | Neck stiffness, photophobia, CSF pleocytosis | CSF analysis positive; fever prominent |
Investigations
| Test | What it answers | Interpretation |
|---|---|---|
| Serum ammonia | Presence of neurotoxic substrate | Elevated supports HE but normal does not exclude it |
| Liver function panel (ALT, AST, bilirubin, albumin, INR) | Baseline hepatic reserve | High INR / low albumin indicate decompensation |
| Complete blood count | Infection, anemia, leukocytosis | Neutrophilia suggests bacterial precipitant |
| Renal function (creatinine, urea) | Clearance of ammonia | Elevated creatinine worsens HE |
| Serology for hepatitis B/C, HIV | Underlying chronic disease | Positive results guide long‑term management |
| Abdominal ultrasound | Cirrhosis, portal hypertension, focal lesions | Nodular liver, splenomegaly confirm chronic disease |
| Electrolytes (Na, K, Mg) | Electrolyte disturbances that precipitate HE | Hyponatremia or hypokalemia can worsen cerebral edema |
| Arterial blood gas | Acid‑base status, hypoxia | Respiratory alkalosis may accompany hyperventilation in HE |
| EEG (if available) | Diffuse slowing vs focal epileptiform activity | Generalized slowing supports metabolic encephalopathy |
| Stool culture / ova‑parasite exam (if diarrhoea) | Infective precipitant (e.g., amoebiasis) | Positive guides antimicrobial therapy |
Diagnosis and severity
Diagnosis is clinical, supported by laboratory evidence of liver dysfunction and exclusion of alternative causes. The presence of any grade of altered mental status in a patient with known or suspected liver disease, together with at least one precipitating factor, confirms hepatic encephalopathy.
Severity grading follows the West‑Haven criteria:
| Grade | Clinical picture | Typical management focus |
|---|---|---|
| 0 | No detectable changes (minimal HE) – only neuropsych testing | Early lactulose, identify precipitant |
| 1 | Trivial lack of awareness, euphoria or anxiety, mild asterixis | Oral lactulose, consider rifaximin |
| 2 | Lethargy, disorientation to time, obvious asterixis | Nasogastric lactulose, start rifaximin |
| 3 | Somnolence, confusion, inability to perform simple tasks | IV lactulose, aggressive infection control |
| 4 | Coma, unresponsive to pain | ICU care, airway protection, consider liver transplant referral |
Severity guides the intensity of monitoring (e.g., need for ICU, invasive ventilation) and the urgency of definitive therapies such as liver transplantation.
Management
Immediate stabilisation
| Step | What to do | Rationale |
|---|---|---|
| Airway & breathing | Give supplemental O₂; consider non‑invasive ventilation if GCS ≤ 10 or CO₂ retention | Prevent hypoxia‑hypercapnia which worsens cerebral edema |
| Circulatory support | Give IV crystalloids to maintain MAP ≥ 65 mmHg; treat sepsis aggressively | Adequate perfusion reduces ammonia production from gut ischemia |
| Identify precipitants | Stop sedatives, correct electrolyte disturbances (especially Na⁺ < 130 mmol/L, Mg²⁺ < 0.7 mmol/L), treat infection, stop GI bleed | Removing triggers halts the acute rise in neurotoxins |
| Lactulose (first‑line gut‑decontaminant) | Administer orally or via NG tube; titrate to 2–3 soft stools/24 h | Acidifies colonic lumen, traps NH₃ as NH₄⁺ and reduces absorption |
| Rifaximin (add‑on) | Give when lactulose alone insufficient or recurrent episodes | Broad‑spectrum gut‑restricted antibiotic lowers ammonia‑producing bacteria |
| Correct hyponatraemia | Raise Na⁺ cautiously (≤ 10 mmol/L/24 h) with hypertonic saline if severe symptomatic | Rapid shifts precipitate cerebral oedema |
Definitive/long‑term treatment
- Secondary prophylaxis: Continue lactulose lifelong; add rifaximin for frequent relapses.
- Nutritional optimisation: Provide 1.2–1.5 g protein/kg/day (vegetable‑based, branched‑chain amino acid supplements if needed) – protein restriction worsens catabolism.
- Manage underlying liver disease:
- Antiviral therapy for HBV/HCV, ART for HIV, anti‑TB drugs with hepatic‑friendly regimens.
- Endoscopic variceal ligation or beta‑blockers for portal hypertension.
- Consider liver transplantation for refractory HE (Grade III–IV) with MELD > 15.
- Avoid precipitants: Educate on avoiding alcohol, constipation, NSAIDs, and over‑the‑counter sedatives.
Monitoring and follow‑up
- Neurological status (GCS, West‑Haven grade) every 2–4 h in acute phase.
- Serum ammonia (trend, not single value).
- Electrolytes, renal function, and arterial blood gases daily.
- Stool frequency and consistency.
- Outpatient review at 2 weeks, then monthly; assess adherence to lactulose, nutrition, and control of precipitating diseases.
Contra‑indications & safety
- Lactulose contraindicated in complete intestinal obstruction.
- Rifaximin should be avoided in patients with known hypersensitivity to rifamycins.
- Hypertonic saline only for severe symptomatic hyponatraemia; monitor serum Na⁺ closely.
- Sedatives, opioids, and anticholinergics are contraindicated during an acute episode.
Complications and prognosis
| Complication | Clinical impact | Management tip |
|---|---|---|
| Cerebral oedema | Can progress to coma, brain herniation | Maintain normocapnia, avoid rapid Na⁺ correction, consider mannitol if signs of raised ICP |
| Falls & aspiration | Due to impaired consciousness | Elevate head of bed, swallow assessment, early physiotherapy |
| Infections (SBP, pneumonia) | Frequently precipitate recurrent HE | Prophylactic antibiotics in high‑risk cirrhotics, early culture‑directed therapy |
| Renal dysfunction (HRS) | Worsens ammonia clearance | Albumin + vasoconstrictor therapy, avoid nephrotoxins |
| Nutritional depletion | Muscle wasting → more ammonia | Early dietitian input, BCAA supplementation |
| Poor long‑term survival | Grade III–IV HE predicts 1‑year mortality > 50 % | Early transplant referral, aggressive management of portal hypertension |
Prognosis improves markedly when precipitating factors are rapidly corrected and secondary prophylaxis is maintained. Recurrent episodes signal advancing liver disease and merit transplant evaluation.
High‑yield exam points
- Look‑alike conditions: Wernicke’s encephalopathy, hypoglycaemia, drug‑induced sedation, sepsis‑associated delirium.
- Commonest wrong first step: Giving sedatives or antipsychotics before ruling out HE; examiners expect you to first look for precipitants and start lactulose.
- Bedside examiner questions:
- “What does a flapping tremor indicate about the severity of HE?”
- “How would you differentiate Grade II from Grade III HE on exam?”
- “Why is it unsafe to give a rapid bolus of normal saline in a hyponatraemic patient with HE?”
- “Explain the role of gut‑derived ammonia versus systemic inflammation in this patient’s encephalopathy.”
Clinical case
Case: A 48‑year‑old man with known alcoholic cirrhosis (Child‑Pugh B) presents to the emergency department after his wife found him confused, disoriented to time, and with asterixis. Vital signs: BP 110/70 mmHg, HR 98 bpm, RR 22, SpO₂ 94 % on room air. Labs: Na⁺ 128 mmol/L, K⁺ 3.4 mmol/L, creatinine 1.6 mg/dL, ammonia 110 µmol/L. No fever; abdominal exam shows tense ascites.
Questions
- What is the most appropriate immediate intervention?
Answer: Start lactulose via NG tube to achieve 2–3 soft stools per day and correct hyponatraemia cautiously with hypertonic saline if symptomatic.
- Which precipitating factor is most likely in this patient?
Answer: Hyponatraemia secondary to diuretic over‑use and reduced oral intake, a common trigger for HE in cirrhotics.
- What long‑term strategy will reduce his risk of future episodes?
Answer: Lifelong lactulose, add rifaximin for secondary prophylaxis, strict alcohol abstinence, nutritional optimisation, and referral for transplant assessment given recurrent decompensation.
Practice questions
Question 1
A 55‑year‑old woman with hepatitis B cirrhosis is brought in with disorientation, slurred speech, and asterixis. Her MAP is 58 mmHg. What is the next best step?
A. Give IV bolus of normal saline
B. Start norepinephrine infusion to raise MAP above 65 mmHg
C. Administer oral lactulose immediately
D. Intubate and hyperventilate
Answer: B. the correct option is to support circulation and maintain MAP ≥ 65 mmHg to ensure cerebral perfusion.
Question 2
A patient with HIV‑related cirrhosis develops Grade II HE. Serum ammonia is mildly elevated. Which medication should be added if lactulose alone is insufficient?
A. Metronidazole
B. Rifaximin
C. Neomycin
D. Ciprofloxacin
Answer: B. rifaximin is the gut‑restricted antibiotic of choice for add‑on therapy.
Question 3
Which of the following findings would push you to classify a patient’s HE as Grade IV?
A. Disorientation to place only
B. Asterixis present bilaterally
C. Somnolence with inability to be aroused
D. Mild agitation with tremor
Answer: C. coma with no response to painful stimulus defines Grade IV.
Question 4
A 30‑year‑old with sickle‑cell disease and chronic liver disease presents with confusion. He is on chronic morphine for pain. Which action is most appropriate?
A. Increase morphine dose for comfort
B. Stop all opioids immediately
C. Replace morphine with a short‑acting opioid and start lactulose
D. Give naloxone bolus
Answer: C. opioid sedation can precipitate HE; replace with a short‑acting agent and start lactulose.
Question 5
A patient with malaria‑induced hepatic dysfunction develops HE. Which of the following is a contraindication to giving lactulose?
A. Grade III encephalopathy
B. Serum Na⁺ 125 mmol/L
C. Ongoing gastrointestinal bleed
D. Complete small‑bowel obstruction
Answer: D. lactulose is contraindicated in complete intestinal obstruction because it cannot reach the colon to exert its effect.
Drafted with AI assistance from standard references and reviewed for structure. Check details against your lecture notes and the Kenya MoH guideline.